Simon Haas
Group leader
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (22)
A balanced SUMOylation equilibrium safeguards the functional anti‐tumor immune response. Oncogene activation drives SUMOylation, rendering aberrant SUMOylation a hallmark of cancer. To delineate the impact of activated SUMOylation on the tumor‐immune synapse, we applied HLA class‐I‐targeted ligandomics and identified a function of activated SUMOylation in restricting the immunopeptidome landscape. Importantly, aberrant SUMOylation suppressed a unique HLA‐I peptide and oncoprotein‐derived neoepitope repertoire, enabling cancer cells to evade T cell immune surveillance. Mechanistically, SUMOylation impaired the immunoproteasome constitution and proteolytic activity, thus limiting the diversity of the peptide landscape. Further, SUMOylation altered TAP1 transporter binding preferences, thereby mimicking viral immune evasion strategies. As an actionable application, pharmacological inhibition of SUMOylation unmasked the targetable immunopeptidome, enhanced the tumor cell susceptibility to T cell killing and substantially reshaped the immune cell landscape. These findings highlight SUMOylation as a critical regulator of the adaptive anti‐tumor immune response. We propose SUMOylation inhibition as a strategy to enhance immunogenic peptide presentation, thereby improving the efficacy of cancer immunotherapies.
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Persistent fetal gene expression in childhood neoplasms is usually explained by a maturation block originating in the prenatal phase. In contrast, reactivation of fetal genes in adult malignancies is considered a consequence of oncofetal reprogramming (OFR) and is associated with aggressive disease. By reconstructing epigenetic ontogeny in juvenile myelomonocytic leukemia (JMML), we identified a postnatal maturation state of JMML stem cells with high transcriptional plasticity indicative of OFR in high-risk disease. Similarly, postnatal activation of oncogenic signaling by inducible Ptpn11E76K mutation in mice triggered molecular plasticity and reactivation of fetal gene expression. Integrative multi-omics analysis revealed aberrant CD52 expression as a feature of high-risk JMML stem cells. Anti-CD52 treatment depleted JMML stem cells and blocked disease propagation in xenograft models. Our results challenge the prevailing maturation block model of pediatric leukemogenesis and establish RAS-associated stem cell plasticity as a determinant of OFR and potential therapeutic vulnerabilities in high-risk JMML. Significance: Persistent fetal gene expression in pediatric malignancies is considered a consequence of prenatal maturation blockade. In this study, we demonstrate that oncogenic PTPN11 mutations enhance cellular plasticity. This leads to partial restoration of fetal molecular programs, creating new therapeutically exploitable vulnerabilities. See commentary by Miao and Xu, pp. XX.
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Collaborators (33)
Gerald Willimsky
Professor
Charité - Universitätsmedizin Berlin
Fredrik Swartling
SciLifeLab Group Leader; Director of the Preclinical Cancer Treatment (PCT) Center
Uppsala University
Maja C Funk
Junior Group Leader
Helmholtz Zentrum München Deutsches Forschungszentrum für Umwelt und Gesundheit
Michael Korenkov
Charité - Universitätsmedizin Berlin
Hans Binder
Managing Director
Leipzig University
Anja E. Hauser
-
Antigoni Triantafyllopoulou
Prof. Dr.
Charité - Universitätsmedizin Berlin
Gerrit Wolters-Eisfeld
University Medical Center Hamburg-Eppendorf
Ulrich Keller
Prof. Dr.
Charité - Universitätsmedizin Berlin
Martin Klatt
Charité - Universitätsmedizin Berlin
Jan Krönke
Professor
Charité - Universitätsmedizin Berlin
Daniel Hübschmann
Research Group Leader
Deutsches Krebsforschungszentrum
Stefan Müller
Goethe University Frankfurt
Silvana Libertini
Lab head
Novartis Institutes for BioMedical Research Basel
Christian H. Bucher
Charité - Universitätsmedizin Berlin
Florian Kurth
Bernhard-Nocht-Institut für Tropenmedizin
Lukas John
Deutsches Krebsforschungszentrum
Jessica Taylor
Assistant Research Professor
University of Cambridge
Kai Tan
Professor
University of Pennsylvania
Julia E. Neumann
Prof. Dr. med
University Medical Center Hamburg-Eppendorf
Francis Baumgartner
Charité - Universitätsmedizin Berlin
Sandy Kroh
Charité - Universitätsmedizin Berlin
Jonathan Seidman
Professor
Harvard University
Henry Loeffler-Wirth
Research group leader
Leipzig University
Michael Hundemer
Professor
University Hospital Heidelberg
Ingram Iaccarino
Scientist
Kiel University
Carsten Watzl
Scientific Director
Leibniz-Institut für Arbeitsforschung an der TU Dortmund
Karsten Rippe
Head of Division
German Cancer Research Center (DKFZ)
Carsten Müller-Tidow
Medical Director
University Hospital Heidelberg
Helene Kretzmer
Professor and Chair Computational Genomics
Hasso Plattner Institute
Marc S. Raab
University Hospital Heidelberg
Judith B. Zaugg
University of Basel
Birgit Sawitzki
University Professor
Berlin Institute of Health at Charité - Universitätsmedizin Berlin
Make your next move.
Prepare your application
Review drafts before you send them.